Cargando…

Low-Dose Naltrexone (LDN) for Chronic Pain at a Single Institution: A Case Series

PURPOSE: Low-dose naltrexone (LDN) has increased in popularity as a non-opioid medication that may decrease chronic pain symptoms. LDN is most commonly used to treat fibromyalgia, complex regional pain syndrome (CRPS), and painful diabetic neuropathy. Other studies suggest that LDN provides general...

Descripción completa

Detalles Bibliográficos
Autores principales:	McKenzie-Brown, Anne Marie, Boorman, David W, Ibanez, Kristen R, Agwu, Ezihe, Singh, Vinita
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10276990/ https://www.ncbi.nlm.nih.gov/pubmed/37337611 http://dx.doi.org/10.2147/JPR.S389957

Ejemplares similares

Low-Dose Naltrexone (LDN)—Review of Therapeutic Utilization
por: Toljan, Karlo, et al.
Publicado: (2018)

Treatment of Complex Regional Pain Syndrome (CRPS) Using Low Dose Naltrexone (LDN)
por: Chopra, Pradeep, et al.
Publicado: (2013)

The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain
por: Younger, Jarred, et al.
Publicado: (2014)

No change in the consumption of thyroid hormones after starting low dose naltrexone (LDN): a quasi-experimental before-after study
por: Raknes, Guttorm, et al.
Publicado: (2020)

A sudden and unprecedented increase in low dose naltrexone (LDN) prescribing in Norway. Patient and prescriber characteristics, and dispense patterns. A drug utilization cohort study
por: Raknes, Guttorm, et al.
Publicado: (2016)

Low-dose naltrexone for the induction of remission in patients with mild to moderate Crohn’s disease: protocol for the randomised, double-blinded, placebo-controlled, multicentre LDN Crohn study
por: Paulides, Emma, et al.
Publicado: (2022)

Study protocol for a randomised, double-blinded, placebo-controlled phase III trial examining the add-on efficacy, cost–utility and neurobiological effects of low-dose naltrexone (LDN) in patients with fibromyalgia (INNOVA study)
por: Colomer-Carbonell, Ariadna, et al.
Publicado: (2022)

Low-Dose Naltrexone in Rheumatological Diseases
por: de Carvalho, Jozélio Freire, et al.
Publicado: (2023)

Low-Dose Naltrexone Use in Postural Orthostatic Tachycardia Syndrome: A Case Series
por: Stallkamp Tidd, Samantha J, et al.
Publicado: (2023)

Low-Dose Naltrexone for Pruritus in Systemic Sclerosis
por: Frech, Tracy, et al.
Publicado: (2011)

The Effects of Low Dose Naltrexone on Opioid Induced Hyperalgesia and Fibromyalgia
por: Jackson, Daniel, et al.
Publicado: (2021)

Jessica Soldavini, MPH, RD, LDN, Wins Huddleson Award
Publicado: (2020)

Low-dose Naltrexone: An Alternative Treatment for Erythrodermic Psoriasis
por: Beltran Monasterio, Eduardo P
Publicado: (2019)

Treatment of psoriasis vulgaris using low-dose naltrexone
por: Bridgman, Alanna C., et al.
Publicado: (2018)

Low-dose naltrexone’s utility for non-cancer centralized pain conditions: a scoping review
por: Rupp, Adam, et al.
Publicado: (2023)

Sjogren's Syndrome: Clinical Benefits of Low-dose Naltrexone Therapy
por: Zashin, Scott
Publicado: (2019)

Low-dose naltrexone as a treatment for chronic fatigue syndrome
por: Bolton, Monica Jane, et al.
Publicado: (2020)

Low dose Naltrexone for induction of remission in inflammatory bowel disease patients
por: Lie, Mitchell R. K. L., et al.
Publicado: (2018)

Low Dose Naltrexone and Lung Cancer: A Case Report and Discussion
por: Miskoff, Jeffrey A, et al.
Publicado: (2018)

Low-Dose Naltrexone Co-Treatment in the Prevention of Opioid-Induced Hyperalgesia
por: Shaheed, Gurneet, et al.
Publicado: (2021)

Naltrexone/Bupropion: Contrave®; Naltrexone SR/Bupropion SR
Publicado: (2012)

Treatment-resistant immune thrombocytopenic purpura associated with LDN use in a patient with MS
por: Torkildsen, Øivind, et al.
Publicado: (2014)

The Bone Morphogenetic Protein Signaling Inhibitor LDN-193189 Enhances Metastasis Development in Mice
por: Vollaire, Julien, et al.
Publicado: (2019)

Opiate Antagonists for Chronic Pain: A Review on the Benefits of Low-Dose Naltrexone in Arthritis versus Non-Arthritic Diseases
por: Dara, Praneet, et al.
Publicado: (2023)

Ultra-low dose naltrexone attenuates chronic morphine-induced gliosis in rats
por: Mattioli, Theresa-Alexandra M, et al.
Publicado: (2010)

The Safety and Efficacy of Low-Dose Naltrexone in Patients with Fibromyalgia: A Systematic Review
por: Yang, Juan, et al.
Publicado: (2023)

Low-dose naltrexone as treatment for epidermolysis bullosa pruriginosa–associated refractory pruritus
por: LaMonica, Lauren C., et al.
Publicado: (2023)

Structural basis for the potent and selective binding of LDN-212854 to the BMP receptor kinase ALK2
por: Williams, Eleanor, et al.
Publicado: (2018)

Inhibition of UCHL1 by LDN-57444 attenuates Ang II–Induced atrial fibrillation in mice
por: Bi, Hai-Lian, et al.
Publicado: (2019)

LDN Protects Bone Property Deterioration at Different Hierarchical Levels in T2DM Mice Bone
por: Shitole, Pankaj, et al.
Publicado: (2021)

Randomized, wait-list–controlled pilot study of app-delivered mindfulness for patients reporting chronic pain
por: Mascaro, Jennifer S., et al.
Publicado: (2021)

The use of naltrexone in pathological and problem gambling: A UK case series
por: Ward, Sophie, et al.
Publicado: (2018)

Treatment outcomes of long-acting injectable naltrexone versus oral naltrexone in alcohol use disorder in veterans
por: Leighty, Anne E., et al.
Publicado: (2019)

3494 Naltrexone as a Diagnostic Tool in Ocular Neuropathic Pain
por: Fowler, Nicholas, et al.
Publicado: (2019)

Reduced Pro-Inflammatory Cytokines after Eight Weeks of Low-Dose Naltrexone for Fibromyalgia
por: Parkitny, Luke, et al.
Publicado: (2017)

Intranasal Low-Dose Naltrexone Against Opioid Side Effects: A Preclinical Study
por: Micheli, Laura, et al.
Publicado: (2020)

Sjogren's Syndrome and Clinical Benefits of Low-Dose Naltrexone Therapy: Additional Case Reports
por: Zashin, Scott
Publicado: (2020)

O-Benzoylnaltrexone
por: Yang, Rui, et al.
Publicado: (2013)

Asymmetric synthesis of (–)-naltrexone
por: Dongbang, Sun, et al.
Publicado: (2018)

The Potential Role of Small-Molecule PERK Inhibitor LDN-0060609 in Primary Open-Angle Glaucoma Treatment
por: Rozpędek-Kamińska, Wioletta, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gr0sfo93e9duskmsbi4ipdta1v